DNA methylation of microRNA genes in multiple myeloma

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1629-1638

  Wong, Kwan Yeung ^a   Huang, Xiaojun ^b   Chim, Chor Sang ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGENESIS; CANCER STAGING; CYCLIN D GENE; CYCLIN DEPENDENT KINASE INHIBITOR 2C GENE; DNA DETERMINATION; DNA METHYLATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; MICRORNA 124 1 GENE; MICRORNA 194 2 192 GENE; MICRORNA 203 GENE; MICRORNA 34A GENE; MICRORNA 34B GENE; MICRORNA 34C GENE; MICRORNA GENE; MOLECULAR GENETICS; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR GENE; V MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG B;

EID: 84865566726     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs212     Document Type: Review

References (166)

1. Siegel, R. et al. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 61, 212-236.
2. Landgren, O. et al. (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia, 23, 1691-1697.
3. Kyle, R.A. et al. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med., 346, 564-569.
4. International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol., 121, 749-757.
5. Kyle, R.A. et al. (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med., 356, 2582-2590.
6. Sher, T. et al. (2010) Plasma cell leukaemia and other aggressive plasma cell malignancies. Br. J. Haematol., 150, 418-427.
7. Bergsagel, P.L. et al. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol., 23, 6333-6338.
8. Chng, W.J. et al. (2007) Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res., 67, 2982-2989.
9. Chng, W.J. et al. (2006) Ploidy status rarely changes in myeloma patients at disease progression. Leuk. Res., 30, 266-271.
10. Smadja, N.V. et al. (1998) Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia, 12, 960-969.
11. Chng, W.J. et al. (2005) A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood, 106, 2156-2161.
12. Bergsagel, P.L. et al. (2001) Chromosome translocations in multiple myeloma. Oncogene, 20, 5611-5622.
13. Avet-Loiseau, H. et al. (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 2185-2191.
14. Richelda, R. et al. (1997) A novel chromosomal translocation t(4; 14) (p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood, 90, 4062-4070.
15. Chesi, M. et al. (1998) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood, 92, 3025-3034.
16. Shaughnessy, J.Jr. et al. (2001) Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood, 98, 217-223.
17. Chesi, M. et al. (1998) Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood, 91, 4457-4463.
18. Hanamura, I. et al. (2001) Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn. J. Cancer Res., 92, 638-644.
19. Fonseca, R. et al. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res., 64, 1546-1558.
20. Avet-Loiseau, H., et al. (2000) Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol., 111, 1116-1117.
21. Fonseca, R. et al. (2001) Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia, 15, 981-986.
22. Bergsagel, P.L. et al. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 106, 296-303.
23. Soverini, S. et al. (2003) Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood, 102, 1588-1594.
24. Smadja, N.V. et al. (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98, 2229-2238.
25. Fonseca, R. et al. (2003) The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 102, 2562-2567.
26. Debes-Marun, C.S. et al. (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 17, 427-436.
27. Kuehl, W.M. et al. (2002) Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer, 2, 175-187.
28. Avet-Loiseau, H. et al. (2001) Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood, 98, 3082-3086.
29. Avet-Loiseau, H. et al. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood, 109, 3489-3495.
30. Fonseca, R. et al. (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 23, 2210-2221.
31. Fonseca, R. et al. (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
32. Chng, W.J. et al. (2007) Clinical significance of TP53 mutation in myeloma. Leukemia, 21, 582-584.
33. Avet-Loiseau, H. et al. (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol., 28, 4630-4634.
34. Bezieau, S. et al. (2001) High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat., 18, 212-224.
35. Liu, P. et al. (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88, 2699-2706.
36. Rasmussen, T. et al. (2005) Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood, 105, 317-323.
37. Chng, W.J. et al. (2008) Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia, 22, 2280-2284.
38. Hideshima, T. et al. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer, 7, 585-598.
39. Podar, K. et al. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 23, 10-24.
40. Esteller, M. (2008) Epigenetics in cancer. N. Engl. J. Med., 358, 1148-1159.
41. Laird, P.W. (2005) Cancer epigenetics. Hum. Mol. Genet., 14, R65-R76.
42. Robertson, K.D. (2005) DNA methylation and human disease. Nat. Rev. Genet., 6, 597-610.
43. Herman, J.G. et al. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
44. Jones, P.A. et al. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428.
45. Fazzari, M.J. et al. (2004) Epigenomics: beyond CpG islands. Nat. Rev. Genet., 5, 446-455.
46. Ioshikhes, I.P. et al. (2000) Large-scale human promoter mapping using CpG islands. Nat. Genet., 26, 61-63.
47. Kim, T.H. et al. (2005) A high-resolution map of active promoters in the human genome. Nature, 436, 876-880.
48. Bird, A. (1999) MOLECULAR BIOLOGY: DNA methylation de Novo. Science, 286, 2287-2288.
49. Singal, R. et al. (1999) DNA methylation. Blood, 93, 4059-4070.
50. Robertson, K.D. et al. (2000) DNA methylation: past, present and future directions. Carcinogenesis, 21, 461-467.
51. Chim, C.S. et al. (2002) Hypermethylation of gene promoters in hematological neoplasia. Hematol. Oncol., 20, 167-176.
52. Costello, J.F. et al. (2001) Methylation matters. J. Med. Genet., 38, 285-303.
53. Knudson, A.G. (2001) Two genetic hits (more or less) to cancer. Nat. Rev. Cancer, 1, 157-162.
54. Chim, C.S. et al. (2008) Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin. Lymphoma Myeloma, 8, 331-339.
55. Walker, B.A. et al. (2011) Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood, 117, 553-562.
56. Dahl, C. et al. (2003) DNA methylation analysis techniques. Biogerontology, 4, 233-250.
57. Laird, P.W. (2010) Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet., 11, 191-203.
58. Shen, L. et al. (2007) Methods of DNA methylation analysis. Curr. Opin. Clin. Nutr. Metab. Care, 10, 576-581.
59. Hayatsu, H. et al. (2008) Bisulfite modification for analysis of DNA methylation. Curr. Protoc. Nucleic Acid Chem., 6, 1-6.10.
60. Hayatsu, H. et al. (1970) Reaction of sodium bisulfite with uracil, cytosine, and their derivatives. Biochemistry, 9, 2858-2865.
61. Felsenfeld, G. et al. (1982) Methylation and gene control. Nature, 296, 602-603.
62. Eick, D. et al. (1983) Quantitative determination of 5-methylcytosine in DNA by reverse-phase high-performance liquid chromatography. Anal. Biochem., 135, 165-171.
63. Frommer, M. et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U.S.A., 89, 1827-1831.
64. Herman, J.G. et al. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U.S.A., 93, 9821-9826.
65. Xiong, Z. et al. (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res., 25, 2532-2534.
66. Gonzalgo, M.L. et al. (1997) Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res., 25, 2529-2531.
67. Eads, C.A. et al. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res., 28, E32.
68. Colella, S. et al. (2003) Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. BioTechniques, 35, 146-150.
69. Ronaghi, M. et al. (1996) Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem., 242, 84-89.
70. Ehrich, M. et al. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl. Acad. Sci. U.S.A., 102, 15785-15790.
71. Zilberman, D. et al. (2007) Genome-wide analysis of DNA methylation patterns. Development, 134, 3959-3965.
72. Kondo, Y. et al. (2010) DNA methylation profiling in cancer. Expert Rev. Mol. Med., 12, e23.
73. Zuo, T. et al. (2009) Methods in DNA methylation profiling. Epigenomics, 1, 331-345.
74. Walter, K. et al. (2012) DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin. Cancer Res., 18, 2360-2373.
75. Tsai, H.C. et al. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell, 21, 430-446.
76. Lister, R. et al. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature, 462, 315-322.
77. Kim, J.H. et al. (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res., 21, 1028-1041.
78. Ordway, J.M. et al. (2006) Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis, 27, 2409-2423.
79. Oda, M. et al. (2009) High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res., 37, 3829-3839.
80. Cheung, H.H. et al. (2010) Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br. J. Cancer, 102, 419-427.
81. Yoshinao, R., et al. (2010) Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genom., 11, 137.
82. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
83. Schickel, R. et al. (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene, 27, 5959-5974.
84. Le, M.T. et al. (2009) MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol. Cell. Biol., 29, 5290-5305.
85. Felli, N. et al. (2009) MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica, 94, 479-486.
86. Garzon, R. et al. (2008) MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol., 15, 352-358.
87. Lee, R.C. et al. (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-854.
88. Wightman, B. et al. (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75, 855-862.
89. Lagos-Quintana, M. et al. (2001) Identification of novel genes coding for small expressed RNAs. Science, 294, 853-858.
90. Lau, N.C. et al. (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 294, 858-862.
91. Lee, R.C. et al. (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science, 294, 862-864.
92. Lee, Y. et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J., 23, 4051-4060.
93. Cai, X. et al. (2004) Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA, 10, 1957-1966.
94. Lee, Y. et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature, 425, 415-419.
95. Lee, Y. et al. (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J., 21, 4663-4670.
96. Yi, R. et al. (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev., 17, 3011-3016.
97. Zeng, Y. et al. (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. U.S.A., 100, 9779-9784.
98. Zeng, Y. et al. (2002) Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell, 9, 1327-1333.
99. Garzon, R. et al. (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 111, 3183-3189.
100. Yanaihara, N. et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-198.
101. Fabbri, M. et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A., 104, 15805-15810.
102. Garzon, R. et al. (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113, 6411-6418.
103. Szalmás, A. et al. (2009) Epigenetic alterations in cervical carcinogenesis. Semin. Cancer Biol., 19, 144-152.
104. Hinshelwood, R.A. et al. (2008) Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J. Mol. Med., 86, 1315-1328.
105. Wang, X. et al. (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3, e2557.
106. Jiang, S. et al. (2010) MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res., 70, 3119-3127.
107. Lal, A. et al. (2008) p16INK4a translation suppressed by miR-24. PLoS One, 3, e1864.
108. Pichiorri, F. et al. (2011) MicroRNAs: new players in multiple myeloma. Front. Genet., 2, 22.
109. Benetatos, L. et al. (2012) Deregulated microRNAs in multiple myeloma. Cancer, 118, 878-887.
110. Pichiorri, F. et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. U.S.A., 105, 12885-12890.
111. Roccaro, A.M. et al. (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 113, 6669-6680.
112. Lionetti, M. et al. (2009) Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood, 114, e20-e26.
113. Unno, K. et al. (2009) Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk. Lymphoma, 50, 1865-1871.
114. Gutiérrez, N.C. et al. (2010) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia, 24, 629-637.
115. Zhou, Y. et al. (2010) High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc. Natl. Acad. Sci. U.S.A., 107, 7904-7909.
116. Corthals, S.L. et al. (2011) MicroRNA signatures characterize multiple myeloma patients. Leukemia, 25, 1784-1789.
117. Lionetti, M. et al. (2009) Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes. Chromosomes Cancer, 48, 521-531.
118. Löffler, D. et al. (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 110, 1330-1333.
119. Corthals, S.L. et al. (2010) Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk. Res., 34, 677-681.
120. Deng, S. et al. (2008) Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 7, 2643-2646.
121. Weber, B. et al. (2007) Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle, 6, 1001-1005.
122. Lujambio, A. et al. (2007) CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle, 6, 1455-1459.
123. Vogelstein, B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
124. Avet-Loiseau, H. et al. (1999) P53 deletion is not a frequent event in multiple myeloma. Br. J. Haematol., 106, 717-719.
125. Imamura, J. et al. (1994) p53 in hematologic malignancies. Blood, 84, 2412-2421.
126. Tarasov, V. et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6, 1586-1593.
127. Chang, T.C. et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 26, 745-752.
128. He, L. et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-1134.
129. Raver-Shapira, N. et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell, 26, 731-743.
130. Bommer, G.T. et al. (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol., 17, 1298-1307.
131. Corney, D.C. et al. (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res., 67, 8433-8438.
132. Luan, S. et al. (2010) MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch. Med. Res., 41, 67-74.
133. Zenz, T. et al. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.
134. Mraz, M. et al. (2009) MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk. Lymphoma, 50, 506-509.
135. Mraz, M. et al. (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia, 23, 1159-1163.
136. Zenz, T. et al. (2009) miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 113, 3801-3808.
137. Dijkstra, M.K. et al. (2009) 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia, 23, 625-627.
138. Ji, Q. et al. (2008) Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer, 8, 266.
139. Hwang, C.I. et al. (2011) Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc. Natl. Acad. Sci. U.S.A., 108, 14240-14245.
140. Corney, D.C. et al. (2010) Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res., 16, 1119-1128.
141. Gallardo, E. et al. (2009) miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis, 30, 1903-1909.
142. Lodygin, D. et al. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle, 7, 2591-2600.
143. Tivnan, A. et al. (2011) MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer, 11, 33.
144. Chim, C.S. et al. (2010) Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis, 31, 745-750.
145. Chim, C.S. et al. (2011) Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J. Transl. Med., 9, 197.
146. Wong, K.Y. et al. (2011) DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics, 3, 83-92.
147. Wong, K.Y. et al. (2011) Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood, 118, 5901-5904.
148. Pichiorri, F. et al. (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell, 18, 367-381.
149. Bueno, M.J. et al. (2008) Genetic and epigenetic silencing of micro-RNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell, 13, 496-506.
150. Chim, C.S. et al. (2011) Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J. Cell. Mol. Med., 15, 2760-2767.
151. Furuta, M. et al. (2010) miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 31, 766-776.
152. van Gent, D.C. et al. (2001) Chromosomal stability and the DNA doublestranded break connection. Nat. Rev. Genet., 2, 196-206.
153. Wong, K.Y. et al. (2011) Epigenetic silencing of MIR203 in multiple myeloma. Br. J. Haematol., 154, 569-578.
154. Agirre, X. et al. (2009) Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res., 69, 4443-4453.
155. Silber, J. et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med., 6, 14.
156. Wilting, S.M. et al. (2010) Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer, 9, 167.
157. Lujambio, A. et al. (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res., 67, 1424-1429.
158. Wong, K.Y. et al. (2011) Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One, 6, e19027.
159. Yoo, C.B. et al. (2006) Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov., 5, 37-50.
160. Kaiser, J. (2010) Epigenetic drugs take on cancer. Science, 330, 576-578.
161. Kuendgen, A. et al. (2008) Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol., 87, 601-611.
162. Bader, A.G. et al. (2010) The promise of microRNA replacement therapy. Cancer Res., 70, 7027-7030.
163. Chng, W.J. et al. (2006) Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia, 20, 807-813.
164. Wong, K.Y. (2011) Promoter DNA methylation of tumour suppressor microRNA genes in multiple myeloma. Ph.D. Thesis, Hong Kong: The University of Hong Kong.
165. Toyota, M. et al. (2008) Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res., 68, 4123-4132.
166. Pigazzi, M. et al. (2009) miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res., 69, 2471-2478.